Spartan Capital Securities, LLC
Search documents
Spartan Capital Securities, LLC Serves as Sales Agent in Healthcare Triangle, Inc.'s $20 Million At-the-Market Offering
Globenewswire· 2025-11-24 21:11
Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].
SPARTAN CAPITAL SECURITIES, LLC SERVES AS EXCLUSIVE PLACEMENT AGENT FOR MULTI WAYS HOLDINGS' $1.485 MILLION SECOND TRANCHE, BRINGING TOTAL REGISTERED DIRECT OFFERING TO $2.97 MILLION
Globenewswire· 2025-10-06 14:00
Core Insights - Spartan Capital Securities, LLC announced the closing of the second tranche of a registered direct offering for Multi Ways Holdings Limited, a leading supplier of heavy construction equipment in Singapore and the surrounding region [1][4]. Group 1: Offering Details - The second tranche consisted of 9,000,000 ordinary shares priced at $0.165 per share, along with warrants to purchase an additional 9,000,000 ordinary shares, resulting in aggregate gross proceeds of $1,485,000 from this tranche [2]. - Combined with the first tranche, the total gross proceeds raised through the offering amount to $2,970,000 [2]. Group 2: Warrant Information - Each warrant is exercisable at $0.198 per share and will remain exercisable for five years from the date of issuance [3]. Group 3: Use of Proceeds - Multi Ways intends to use the net proceeds for working capital and general corporate purposes [3]. Group 4: Company Background - Multi Ways Holdings supplies a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, serving customers across Singapore, Australia, UAE, Maldives, Indonesia, and the Philippines [7].
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering
GlobeNewswire News Room· 2025-07-09 21:15
Core Insights - Spartan Capital Securities, LLC announced the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. [1] - The offering involved the sale of 974,026 shares of Common Stock at a public offering price of $1.54 per share [2] - The gross proceeds of approximately $1.5 million will be used for general corporate purposes and working capital [3] Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on cancer drug development [2][8] - The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that enhances the effectiveness of chemotherapy and immunotherapy [8] - Clinical trials are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [8] Transaction Details - The offering was made under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [5] - Spartan Capital Securities served as the exclusive placement agent for this transaction [1][4] - The transaction reflects a focus on aligning innovative biotech companies with strategic capital for advancing therapies [4]
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
Newsfilter· 2025-03-04 18:18
Core Insights - Spartan Capital Securities, LLC successfully completed a $3,788,000 private placement for Lipella Pharmaceuticals Inc. [1] - The proceeds will support Lipella's mission to develop innovative therapies for unmet medical needs and fund general corporate purposes [2] - Spartan Capital's CEO highlighted the strength of Lipella's vision and the firm's commitment to facilitating impactful investment opportunities [3] Company Overview - Lipella Pharmaceuticals is focused on developing groundbreaking clinical therapies aimed at significant medical needs [2] - Spartan Capital Securities is a full-service investment banking firm known for its expertise in capital raising and strategic advisory services [6] Transaction Details - Spartan Capital acted as the sole placement agent for the private offering [1][3] - Legal counsel for the transaction included Sichenzia Ross Ference Carmel LLP for the placement agent and Sullivan & Worcester LLP for Lipella Pharmaceuticals [3] - Further transaction details will be available in Lipella's Form 8-K to be filed with the U.S. Securities and Exchange Commission [4]
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
GlobeNewswire News Room· 2025-03-04 18:18
Group 1 - Spartan Capital Securities, LLC successfully completed a $3,788,000 private placement for Lipella Pharmaceuticals Inc. [1][2] - The proceeds will support Lipella's mission to develop innovative therapies for unmet medical needs and fund general corporate purposes [2] - Jonathan Kaufman, CEO of Lipella, is focused on advancing the company's clinical pipeline and transformative treatments [2] Group 2 - John Lowry, CEO of Spartan Capital, expressed honor in serving as the sole placement agent and highlighted Lipella's commitment to medical innovation [3] - The transaction reflects the strength of Lipella's vision and Spartan Capital's dedication to impactful investment opportunities [3] - Legal counsel for the transaction included Sichenzia Ross Ference Carmel LLP for the placement agent and Sullivan & Worcester LLP for Lipella [3] Group 3 - Further details on the transaction will be available in Lipella's Form 8-K, to be filed with the U.S. Securities and Exchange Commission [4] - The common shares and related warrants have not been registered under the Securities Act of 1933, limiting their sale until registration or exemption [5] - This press release does not constitute an offer to sell or solicit offers to buy the securities [6]
Spartan Capital Securities, LLC Serves as Co-Placement Agent in Healthcare Triangle, Inc.'s $15.2 Million Private Placement
GlobeNewswire News Room· 2025-03-04 13:55
Core Insights - Spartan Capital Securities, LLC successfully completed a $15.2 million private placement for Healthcare Triangle, Inc. to support its expansion and digital transformation initiatives in the healthcare and life sciences sectors [1][2]. Group 1: Financial Details - The proceeds from the private placement will be utilized for strategic acquisitions, general corporate purposes, and working capital needs, enhancing Healthcare Triangle's mission in cloud enablement, cybersecurity, and data analytics solutions [2]. - Spartan Capital Securities played a significant role by placing $14.2 million of the total private placement, highlighting its strong position in the investment banking sector [2]. Group 2: Company Statements - John Lowry, CEO of Spartan Capital Securities, expressed honor in serving as Co-Placement Agent for Healthcare Triangle, emphasizing the company's leadership in digital innovation within healthcare and life sciences [3]. - The successful transaction reflects both Healthcare Triangle's strong vision and Spartan Capital's commitment to facilitating meaningful investment opportunities [3]. Group 3: Legal and Compliance - The securities involved in the offering, including common stock and various warrants, have not been registered under the Securities Act of 1933 or any state securities laws, and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].